Dechra Pharmaceuticals PLC
DCHPF · OTC
6/30/2023 | 12/31/2022 | 6/30/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $384,100 | $377,400 | $349,400 | $332,400 |
| % Growth | 1.8% | 8% | 5.1% | – |
| Cost of Goods Sold | $173,000 | $158,900 | $153,300 | $143,700 |
| Gross Profit | $211,100 | $218,500 | $196,100 | $188,700 |
| % Margin | 55% | 57.9% | 56.1% | 56.8% |
| R&D Expenses | $62,400 | $28,200 | $55,800 | $15,300 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $208,300 | $143,400 | $136,900 | $116,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $263,500 | $179,900 | $167,400 | $131,100 |
| Operating Income | -$29,800 | $46,900 | $38,400 | $57,400 |
| % Margin | -7.8% | 12.4% | 11% | 17.3% |
| Other Income/Exp. Net | -$36,000 | -$17,200 | -$14,200 | -$4,000 |
| Pre-Tax Income | -$65,800 | $29,700 | $24,200 | $53,400 |
| Tax Expense | -$15,300 | $7,100 | $6,700 | $12,700 |
| Net Income | -$50,500 | $22,600 | $17,500 | $40,700 |
| % Margin | -13.1% | 6% | 5% | 12.2% |
| EPS | -0.44 | 0.199 | 0.16 | 0.38 |
| % Growth | -321.6% | 23.8% | -57.8% | – |
| EPS Diluted | -0.44 | 0.199 | 0.16 | 0.38 |
| Weighted Avg Shares Out | 113,305 | 113,095 | 108,393 | 108,882 |
| Weighted Avg Shares Out Dil | 113,858 | 113,824 | 109,083 | 108,892 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13,400 | $8,900 | $0 | $0 |
| Interest Expense | $13,400 | $8,900 | $4,500 | $4,200 |
| Depreciation & Amortization | $36,500 | $8,600 | $32,400 | $7,400 |
| EBITDA | -$15,900 | $47,200 | $61,100 | $64,800 |
| % Margin | -4.1% | 12.5% | 17.5% | 19.5% |